Teriparatide Acetate
Cas No. 52232-67-4
Molecular Formula C181H291N55O51S2
Masse moléculaire 41177.72
Pureté (CLHP: Ge; 98.5%
Appearance White powder
Used: APIs , postmenopausal women with osteoporosis;Protected amino acids; peptides
Applications &Fuction
Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget’s Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
